Search

Your search keyword '"Porta, Nuria"' showing total 255 results
Start Over Author "Porta, Nuria"
255 results on '"Porta, Nuria"'

2. RNASEH2B loss and PARP inhibition in advanced prostate cancer

Author

Carmichael, Juliet, Figueiredo, Ines, Gurel, Bora, Beije, Nick, Yuan, Wei, Rekowski, Jan, Seed, George, Carreira, Suzanne, Bertan, Claudia, de La Maza, Maria de Los Dolores Fenor, Chandran, Khobe, Neeb, Antje, Welti, Jon, Gallagher, Lewis, Bogdan, Denisa, Crespo, Mateus, Riisnaes, Ruth, Ferreira, Ana, Miranda, Susana, Lu, Jinqiu, Shen, Michael M., Hall, Emma, Porta, Nuria, Westaby, Daniel, Guo, Christina, Grochot, Rafael, Lord, Christopher J., Mateo, Joaquin, Sharp, Adam, and de Bono, Johann

Subjects
Oncology, Experimental, Prostate cancer -- Development and progression -- Genetic aspects -- Care and treatment, Enzyme inhibitors -- Research, Ribonuclease -- Health aspects, Cellular proteins -- Health aspects, Cancer -- Research
Abstract

BACKGROUND. Clinical trials have suggested antitumor activity from PARP inhibition beyond homologous recombination deficiency (HRD). RNASEH2B loss is unrelated to HRD and preclinically sensitizes to PARP inhibition. The current study reports on RNASEH2B protein loss in advanced prostate cancer and its association with RB1 protein loss, clinical outcome, and clonal dynamics during treatment with PARP inhibition in a prospective clinical trial. METHODS. Whole tumor biopsies from multiple cohorts of patients with advanced prostate cancer were interrogated using whole-exome sequencing (WES), RNA-Seq (bulk and single nucleus), and IHC for RNASEH2B and RB1. Biopsies from patients treated with olaparib in the TOPARP-A and TOPARP-B clinical trials were used to evaluate RNASEH2B clonal selection during olaparib treatment. RESULTS. Shallow codeletion of RNASEH2B and adjacent RB1--colocated at chromosome 13q14--was common, deep codeletion infrequent, and gene loss associated with lower mRNA expression. In castration-resistant prostate cancer (CRPC) biopsies, RNASEH2B and RB1 mRNA expression correlated, but single nucleus RNA-Seq indicated discordant loss of expression. IHC studies showed that loss of the 2 proteins often occurred independently, arguably due to stochastic second allele loss. Pre- and posttreatment metastatic CRPC (mCRPC) biopsy studies from BRCA1/2 WT tumors, treated on the TOPARP phase II trial, indicated that olaparib eradicated RNASEH2B-loss tumor subclones. CONCLUSION. PARP inhibition may benefit men suffering from mCRPC by eradicating tumor subclones with RNASEH2B loss. TRIAL REGISTRATION. Clinicaltrials.gov NCT01682772. FUNDING. AstraZeneca; Cancer Research UK; Medical Research Council; Cancer Research UK; Prostate Cancer UK; Movember Foundation; Prostate Cancer Foundation., Introduction Prostate cancer (PC) is the second most common male malignancy worldwide, with over 1.4 million cases and 375,000 deaths per year (1). Progression to metastatic castration-resistant PC (mCRPC) after [...]

Published
2024
Full Text
View/download PDF

3. Results of the implementation of the DP-TRANSFERS project in Catalonia: a translational method to improve diabetes screening and prevention in primary care

Author

Costa, Bernardo, Castell, Conxa, Cabré, Joan-Josep, García-Barco, Montserrat, Barrio, Francesc, Sagarra, Ramon, Mestre, Santiago, Jardí, Cristina, Flores, Gemma, Basora, Josep, Dalmau, Susanna, Cos, Xavier, Canela, Marta, Solé, Claustre, Martínez, Ana, Mur, Teresa, López, Charo, Roca, Montserrat, Porta, Núria, Aguilar, Sofía, Boquet, Antoni, Carreiro, Miguel-Ángel, Pujol, Francesc, Bueno, Juan-Luis, Bonfill, Mercè, Nadal, Montserrat, Alum, Albert, García, Concepción, Capdevila, Alba, Gómez, Ana, Roura, Marta, Llens, Anna, Cabré, J.J., Barrio, F., Vizcaíno, J., Martínez, A., Mur, T., Sagarra, R., and Dalmau, S.

Published
2024
Full Text
View/download PDF

4. Resultados de la implementación del proyecto DP-TRANSFERS en Cataluña: un método traslacional para mejorar el cribado y la prevención de la diabetes en atención primaria

Author

Costa, Bernardo, Castell, Conxa, Cabré, Joan-Josep, García-Barco, Montserrat, Barrio, Francesc, Sagarra, Ramon, Mestre, Santiago, Jardí, Cristina, Flores, Gemma, Basora, Josep, Dalmau, Susanna, Cos, Xavier, Canela, Marta, Solé, Claustre, Martínez, Ana, Mur, Teresa, López, Charo, Roca, Montserrat, Porta, Núria, Aguilar, Sofía, Boquet, Antoni, Carreiro, Miguel-Ángel, Pujol, Francesc, Bueno, Juan-Luis, Bonfill, Mercè, Nadal, Montserrat, Alum, Albert, García, Concepción, Capdevila, Alba, Gómez, Ana, Roura, Marta, Llens, Anna, Cabré, J.J., Barrio, F., Vizcaíno, J., Martínez, A., Mur, T., Sagarra, R., and Dalmau, S.

Published
2024
Full Text
View/download PDF

5. Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial

Author

Rescigno, Pasquale, Porta, Nuria, Finneran, Laura, Riisnaes, Ruth, Figueiredo, Ines, Carreira, Suzanne, Flohr, Penny, Miranda, Susana, Bertan, Claudia, Ferreira, Ana, Crespo, Mateus, Rodrigues, Daniel Nava, Gurel, Bora, Nobes, Jenny, Crabb, Simon, Malik, Zafar, Ralph, Christy, McGovern, Ursula, Hoskin, Peter, Jones, Robert J., Birtle, Alison, Gale, Joanna, Sankey, Peter, Jain, Suneil, McLaren, Duncan, Chadwick, Eliot, Espinasse, Aude, Hall, Emma, and de Bono, Johann

Published
2024
Full Text
View/download PDF

6. Nilotinib in KIT-driven advanced melanoma: Results from the phase II single-arm NICAM trial

Author

Larkin, James, Marais, Richard, Porta, Nuria, Gonzalez de Castro, David, Parsons, Lisa, Messiou, Christina, Stamp, Gordon, Thompson, Lisa, Edmonds, Kim, Sarker, Sarah, Banerji, Jane, Lorigan, Paul, Evans, Thomas R. Jeffry, Corrie, Pippa, Marshall, Ernest, Middleton, Mark R., Nathan, Paul, Nicholson, Steve, Ottensmeier, Christian, Plummer, Ruth, Bliss, Judith, Valpione, Sara, and Turajlic, Samra

Published
2024
Full Text
View/download PDF

8. Image quality in whole-body MRI using the MY-RADS protocol in a prospective multi-centre multiple myeloma study

Author

Keaveney, Sam, Dragan, Alina, Rata, Mihaela, Blackledge, Matthew, Scurr, Erica, Winfield, Jessica M., Shur, Joshua, Koh, Dow-Mu, Porta, Nuria, Candito, Antonio, King, Alexander, Rennie, Winston, Gaba, Suchi, Suresh, Priya, Malcolm, Paul, Davis, Amy, Nilak, Anjumara, Shah, Aarti, Gandhi, Sanjay, Albrizio, Mauro, Drury, Arnold, Pratt, Guy, Cook, Gordon, Roberts, Sadie, Jenner, Matthew, Brown, Sarah, Kaiser, Martin, and Messiou, Christina

Published
2023
Full Text
View/download PDF

10. First-in-human technique translation of oxygen-enhanced MRI to an MR Linac system in patients with head and neck cancer

Author

Dubec, Michael J., Buckley, David L., Berks, Michael, Clough, Abigael, Gaffney, John, Datta, Anubhav, McHugh, Damien J., Porta, Nuria, Little, Ross A., Cheung, Susan, Hague, Christina, Eccles, Cynthia L., Hoskin, Peter J., Bristow, Robert G., Matthews, Julian C., van Herk, Marcel, Choudhury, Ananya, Parker, Geoff J.M., McPartlin, Andrew, and O'Connor, James P.B.

Published
2023
Full Text
View/download PDF

13. METRADS-P vs. RECIST/PCWG criteria to detect disease progression in metastatic castration-resistant prostate cancer (mCRPC).

Author

Tunariu, Nina, primary, Avesani, Giacomo, additional, Russo, Luca, additional, Porta, Nuria, additional, Withey, Sam, additional, Abramowicz, Katarzina, additional, Biscombe, Katie, additional, Bottazzi, Silvia, additional, Hujairi, Nabil, additional, Ribeiro, Ana Sofia, additional, Taha, Tarek, additional, Longoria-Lozano, Ossian, additional, Jacobs, Tiaan, additional, Emsley, Robby, additional, Vit, Sharon, additional, Sala, Evis, additional, Messiou, Christina, additional, Koh, Dow-Mu, additional, Sharp, Adam, additional, and De Bono, Johann S., additional

Published
2024
Full Text
View/download PDF

18. The 111 Study: A Single-arm, Phase 3 Trial Evaluating One Cycle of Bleomycin, Etoposide, and Cisplatin as Adjuvant Chemotherapy in High-risk, Stage 1 Nonseminomatous or Combined Germ Cell Tumours of the Testis

Author

Cullen, Michael, Huddart, Robert, Joffe, Johnathan, Gardiner, Deborah, Maynard, Lauren, Hutton, Paul, Mazhar, Danish, Shamash, Jonathan, Wheater, Matthew, White, Jeff, Goubar, Aicha, Porta, Nuria, Witts, Stephanie, Lewis, Rebecca, and Hall, Emma

Published
2020
Full Text
View/download PDF

21. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial

Author

Mateo, Joaquin, Porta, Nuria, Bianchini, Diletta, McGovern, Ursula, Elliott, Tony, Jones, Robert, Syndikus, Isabel, Ralph, Christy, Jain, Suneil, Varughese, Mohini, Parikh, Omi, Crabb, Simon, Robinson, Angus, McLaren, Duncan, Birtle, Alison, Tanguay, Jacob, Miranda, Susana, Figueiredo, Ines, Seed, George, Bertan, Claudia, Flohr, Penny, Ebbs, Berni, Rescigno, Pasquale, Fowler, Gemma, Ferreira, Ana, Riisnaes, Ruth, Pereira, Rita, Curcean, Andra, Chandler, Robert, Clarke, Matthew, Gurel, Bora, Crespo, Mateus, Nava Rodrigues, Daniel, Sandhu, Shahneen, Espinasse, Aude, Chatfield, Peter, Tunariu, Nina, Yuan, Wei, Hall, Emma, Carreira, Suzanne, and de Bono, Johann S

Published
2020
Full Text
View/download PDF

22. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

Author

Mateo, Joaquin, Carreira, Suzanne, Sandhu, Shahneen, Miranda, Susana, Mossop, Helen, Perez-Lopez, Raquel, Nava Rodrigues, Daniel, Robinson, Dan, Omlin, Aurelius, Tunariu, Nina, Boysen, Gunther, Porta, Nuria, Flohr, Penny, Gillman, Alexa, Figueiredo, Ines, Paulding, Claire, Seed, George, Jain, Suneil, Ralph, Christy, Protheroe, Andrew, Hussain, Syed, Jones, Robert, Elliott, Tony, McGovern, Ursula, Bianchini, Diletta, Goodall, Jane, Zafeiriou, Zafeiris, Williamson, Chris T, Ferraldeschi, Roberta, Riisnaes, Ruth, Ebbs, Bernardette, Fowler, Gemma, Roda, Desamparados, Yuan, Wei, Wu, Yi-Mi, Cao, Xuhong, Brough, Rachel, Pemberton, Helen, A'Hern, Roger, Swain, Amanda, Kunju, Lakshmi P, Eeles, Rosalind, Attard, Gerhardt, Lord, Christopher J, Ashworth, Alan, Rubin, Mark A, Knudsen, Karen E, Feng, Felix Y, Chinnaiyan, Arul M, Hall, Emma, and de Bono, Johann S

Subjects
Genetics, Urologic Diseases, Human Genome, Prostate Cancer, Cancer, Clinical Research, 6.1 Pharmaceuticals, 6.2 Cellular and gene therapies, Evaluation of treatments and therapeutic interventions, 4.1 Discovery and preclinical testing of markers and technologies, Detection, screening and diagnosis, Adult, Aged, Anemia, Antineoplastic Agents, Ataxia Telangiectasia Mutated Proteins, DNA Repair, Drug Resistance, Neoplasm, Enzyme Inhibitors, Fatigue, Genes, BRCA2, Genes, Tumor Suppressor, Humans, Male, Middle Aged, Mutation, Neoplasm Metastasis, Phthalazines, Piperazines, Poly(ADP-ribose) Polymerase Inhibitors, Prostatic Neoplasms, Medical and Health Sciences, General & Internal Medicine
Abstract

BackgroundProstate cancer is a heterogeneous disease, but current treatments are not based on molecular stratification. We hypothesized that metastatic, castration-resistant prostate cancers with DNA-repair defects would respond to poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibition with olaparib.MethodsWe conducted a phase 2 trial in which patients with metastatic, castration-resistant prostate cancer were treated with olaparib tablets at a dose of 400 mg twice a day. The primary end point was the response rate, defined either as an objective response according to Response Evaluation Criteria in Solid Tumors, version 1.1, or as a reduction of at least 50% in the prostate-specific antigen level or a confirmed reduction in the circulating tumor-cell count from 5 or more cells per 7.5 ml of blood to less than 5 cells per 7.5 ml. Targeted next-generation sequencing, exome and transcriptome analysis, and digital polymerase-chain-reaction testing were performed on samples from mandated tumor biopsies.ResultsOverall, 50 patients were enrolled; all had received prior treatment with docetaxel, 49 (98%) had received abiraterone or enzalutamide, and 29 (58%) had received cabazitaxel. Sixteen of 49 patients who could be evaluated had a response (33%; 95% confidence interval, 20 to 48), with 12 patients receiving the study treatment for more than 6 months. Next-generation sequencing identified homozygous deletions, deleterious mutations, or both in DNA-repair genes--including BRCA1/2, ATM, Fanconi's anemia genes, and CHEK2--in 16 of 49 patients who could be evaluated (33%). Of these 16 patients, 14 (88%) had a response to olaparib, including all 7 patients with BRCA2 loss (4 with biallelic somatic loss, and 3 with germline mutations) and 4 of 5 with ATM aberrations. The specificity of the biomarker suite was 94%. Anemia (in 10 of the 50 patients [20%]) and fatigue (in 6 [12%]) were the most common grade 3 or 4 adverse events, findings that are consistent with previous studies of olaparib.ConclusionsTreatment with the PARP inhibitor olaparib in patients whose prostate cancers were no longer responding to standard treatments and who had defects in DNA-repair genes led to a high response rate. (Funded by Cancer Research UK and others; ClinicalTrials.gov number, NCT01682772; Cancer Research UK number, CRUK/11/029.).

Published
2015

23. Elucidating acquired PARP inhibitor resistance in advanced prostate cancer

Author

Seed, George, Beije, Nick, Yuan, Wei, Bertan, Claudia, Goodall, Jane, Lundberg, Arian, Tyler, Matthew, Figueiredo, Ines, Pereira, Rita, Baker, Chloe, Bogdan, Denisa, Gallagher, Lewis, Cieslik, Jan-Phillipp, Greening, Semini, Lambros, Maryou, Neves, Rui, Magraner-Pardo, Lorena, Fowler, Gemma, Ebbs, Berni, Miranda, Susana, Flohr, Penny, Bianchini, Diletta, Rescigno, Pasquale, Porta, Nuria, Hall, Emma, Gurel, Bora, Tunariu, Nina, Sharp, Adam, Pettit, Stephen, Stoecklein, Nikolas H., Sandhu, Shahneen, Quigley, David, Lord, Christopher J., Mateo, Joaquin, Carreira, Suzanne, and de Bono, Johann

Published
2024
Full Text
View/download PDF

24. BOXIT—A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004)

Author

Kelly, John D., Tan, Wei Shen, Porta, Nuria, Mostafid, Hugh, Huddart, Robert, Protheroe, Andrew, Bogle, Richard, Blazeby, Jane, Palmer, Alison, Cresswell, Jo, Johnson, Mark, Brough, Richard, Madaan, Sanjeev, Andrews, Stephen, Cruickshank, Clare, Burnett, Stephanie, Maynard, Lauren, and Hall, Emma

Published
2019
Full Text
View/download PDF

26. Association of General and Abdominal Obesity With Hypertension, Dyslipidemia and Prediabetes in the PREDAPS Study

Author

Sangrós, F. Javier, Torrecilla, Jesús, Giráldez-García, Carolina, Carrillo, Lourdes, Mancera, José, Mur, Teresa, Franch, Josep, Díez, Javier, Goday, Albert, Serrano, Rosario, García-Soidán, F. Javier, Cuatrecasas, Gabriel, Igual, Dimas, Moreno, Ana, Millaruelo, J. Manuel, Carramiñana, Francisco, Ruiz, Manuel Antonio, Pérez, Francisco Carlos, Iriarte, Yon, Lorenzo, Ángela, González, María, Álvarez, Beatriz, Barutell, Lourdes, Mayayo, M. Soledad, del Castillo, Mercedes, Navarro, Emma, Malo, Fernando, Cambra, Ainhoa, López, Riánsares, Gutiérrez, M. Ángel, Gutiérrez, Luisa, Boente, Carmen, Mediavilla, J. Javier, Prieto, Luis, Mendo, Luis, Mansilla, M. José, Ortega, Francisco Javier, Borras, Antonia, Sánchez, L. Gabriel, Obaya, J. Carlos, Alonso, Margarita, García, Francisco, Gutiérrez, Ángela Trinidad, Hernández, Ana M., Suárez, Dulce, Álvarez, J. Carlos, Sáenz, Isabel, Martínez, F. Javier, Casorrán, Ana, Ripoll, Jazmín, Salanova, Alejandro, Marín, M. Teresa, Gutiérrez, Félix, Innerárity, Jaime, Álvarez, M. del Mar, Artola, Sara, Bedoya, M. Jesús, Poveda, Santiago, Álvarez, Fernando, Brito, M. Jesús, Iglesias, Rosario, Paniagua, Francisca, Nogales, Pedro, Gómez, Ángel, Rubio, José Félix, Durán, M. Carmen, Sagredo, Julio, Gijón, M. Teresa, Rollán, M. Ángeles, Pérez, Pedro P., Gamarra, Javier, Carbonell, Francisco, García-Giralda, Luis, Antón, J. Joaquín, de la Flor, Manuel, Martínez, Rosario, Pardo, José Luis, Ruiz, Antonio, Plana, Raquel, Macía, Ramón, Villaró, Mercè, Babace, Carmen, Torres, José Luis, Blanco, Concepción, Jurado, Ángeles, Martín, José Luis, Navarro, Jorge, Sanz, Gloria, Colas, Rafael, Cordero, Blanca, de Castro, Cristina, Ibáñez, Mercedes, Monzón, Alicia, Porta, Nuria, Gómez, María del Carmen, Llanes, Rafael, Rodríguez, J. José, Granero, Esteban, Sánchez, Manuel, Martínez, Juan, Ezkurra, Patxi, Ávila, Luis, de la Sen, Carlos, Rodríguez, Antonio, Buil, Pilar, Gabriel, Paula, Roura, Pilar, Tarragó, Eduard, Mundet, Xavier, Bosch, Remei, González, J. Carles, Bobé, M. Isabel, Mata, Manel, Ruiz, Irene, López, Flora, Birules, Marti, Armengol, Oriol, de Miguel, Rosa Mar, Romera, Laura, Benito, Belén, Piulats, Neus, Bilbeny, Beatriz, Cabré, J. José, Cos, Xavier, Pujol, Ramón, Seguí, Mateu, Losada, Carmen, de Santiago, A. María, Muñoz, Pedro, and Regidor, Enrique

Published
2018
Full Text
View/download PDF

27. Asociación de obesidad general y abdominal con hipertensión, dislipemia y presencia de prediabetes en el estudio PREDAPS

Author

Sangrós, F. Javier, Torrecilla, Jesús, Giráldez-García, Carolina, Carrillo, Lourdes, Mancera, José, Mur, Teresa, Franch, Josep, Díez, Javier, Goday, Albert, Serrano, Rosario, García-Soidán, F. Javier, Cuatrecasas, Gabriel, Igual, Dimas, Moreno, Ana, Millaruelo, J. Manuel, Carramiñana, Francisco, Ruiz, Manuel Antonio, Pérez, Francisco Carlos, Iriarte, Yon, Lorenzo, Ángela, González, María, Álvarez, Beatriz, Barutell, Lourdes, Mayayo, M. Soledad, del Castillo, Mercedes, Navarro, Emma, Malo, Fernando, Cambra, Ainhoa, López, Riánsares, Gutiérrez, M. Ángel, Gutiérrez, Luisa, Boente, Carmen, Mediavilla, J. Javier, Prieto, Luis, Mendo, Luis, Mansilla, M. José, Ortega, Francisco Javier, Borras, Antonia, Sánchez, L. Gabriel, Obaya, J. Carlos, Alonso, Margarita, García, Francisco, Gutiérrez, Ángela Trinidad, Hernández, Ana M., Suárez, Dulce, Álvarez, J. Carlos, Sáenz, Isabel, Martínez, F. Javier, Casorrán, Ana, Ripoll, Jazmín, Salanova, Alejandro, Marín, M. Teresa, Gutiérrez, Félix, Innerárity, Jaime, Álvarez, M. del Mar, Artola, Sara, Bedoya, M. Jesús, Poveda, Santiago, Álvarez, Fernando, Brito, M. Jesús, Iglesias, Rosario, Paniagua, Francisca, Nogales, Pedro, Gómez, Ángel, Rubio, José Félix, Durán, M. Carmen, Sagredo, Julio, Gijón, M. Teresa, Rollán, M. Ángeles, Pérez, Pedro P., Gamarra, Javier, Carbonell, Francisco, García-Giralda, Luis, Antón, J. Joaquín, de la Flor, Manuel, Martínez, Rosario, Pardo, José Luis, Ruiz, Antonio, Plana, Raquel, Macía, Ramón, Villaró, Mercè, Babace, Carmen, Torres, José Luis, Blanco, Concepción, Jurado, Ángeles, Martín, José Luis, Navarro, Jorge, Sanz, Gloria, Colas, Rafael, Cordero, Blanca, de Castro, Cristina, Ibáñez, Mercedes, Monzón, Alicia, Porta, Nuria, Gómez, María del Carmen, Llanes, Rafael, Rodríguez, J. José, Granero, Esteban, Sánchez, Manuel, Martínez, Juan, Ezkurra, Patxi, Ávila, Luis, de la Sen, Carlos, Rodríguez, Antonio, Buil, Pilar, Gabriel, Paula, Roura, Pilar, Tarragó, Eduard, Mundet, Xavier, Bosch, Remei, González, J. Carles, Bobé, M. Isabel, Mata, Manel, Ruiz, Irene, López, Flora, Birules, Marti, Armengol, Oriol, de Miguel, Rosa Mar, Romera, Laura, Benito, Belén, Piulats, Neus, Bilbeny, Beatriz, Cabré, J. José, Cos, Xavier, Pujol, Ramón, Seguí, Mateu, Losada, Carmen, de Santiago, A. María, Muñoz, Pedro, and Regidor, Enrique

Published
2018
Full Text
View/download PDF

32. Data from Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition

Author

Goodall, Jane, primary, Mateo, Joaquin, primary, Yuan, Wei, primary, Mossop, Helen, primary, Porta, Nuria, primary, Miranda, Susana, primary, Perez-Lopez, Raquel, primary, Dolling, David, primary, Robinson, Dan R., primary, Sandhu, Shahneen, primary, Fowler, Gemma, primary, Ebbs, Berni, primary, Flohr, Penny, primary, Seed, George, primary, Rodrigues, Daniel Nava, primary, Boysen, Gunther, primary, Bertan, Claudia, primary, Atkin, Mark, primary, Clarke, Matthew, primary, Crespo, Mateus, primary, Figueiredo, Ines, primary, Riisnaes, Ruth, primary, Sumanasuriya, Semini, primary, Rescigno, Pasquale, primary, Zafeiriou, Zafeiris, primary, Sharp, Adam, primary, Tunariu, Nina, primary, Bianchini, Diletta, primary, Gillman, Alexa, primary, Lord, Christopher J., primary, Hall, Emma, primary, Chinnaiyan, Arul M., primary, Carreira, Suzanne, primary, and de Bono, Johann S., primary

Published
2023
Full Text
View/download PDF

33. Supplementary Figure S2 from Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition

Author

Goodall, Jane, primary, Mateo, Joaquin, primary, Yuan, Wei, primary, Mossop, Helen, primary, Porta, Nuria, primary, Miranda, Susana, primary, Perez-Lopez, Raquel, primary, Dolling, David, primary, Robinson, Dan R., primary, Sandhu, Shahneen, primary, Fowler, Gemma, primary, Ebbs, Berni, primary, Flohr, Penny, primary, Seed, George, primary, Rodrigues, Daniel Nava, primary, Boysen, Gunther, primary, Bertan, Claudia, primary, Atkin, Mark, primary, Clarke, Matthew, primary, Crespo, Mateus, primary, Figueiredo, Ines, primary, Riisnaes, Ruth, primary, Sumanasuriya, Semini, primary, Rescigno, Pasquale, primary, Zafeiriou, Zafeiris, primary, Sharp, Adam, primary, Tunariu, Nina, primary, Bianchini, Diletta, primary, Gillman, Alexa, primary, Lord, Christopher J., primary, Hall, Emma, primary, Chinnaiyan, Arul M., primary, Carreira, Suzanne, primary, and de Bono, Johann S., primary

Published
2023
Full Text
View/download PDF

34. Supplemental Table S1 from Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition

Author

Goodall, Jane, primary, Mateo, Joaquin, primary, Yuan, Wei, primary, Mossop, Helen, primary, Porta, Nuria, primary, Miranda, Susana, primary, Perez-Lopez, Raquel, primary, Dolling, David, primary, Robinson, Dan R., primary, Sandhu, Shahneen, primary, Fowler, Gemma, primary, Ebbs, Berni, primary, Flohr, Penny, primary, Seed, George, primary, Rodrigues, Daniel Nava, primary, Boysen, Gunther, primary, Bertan, Claudia, primary, Atkin, Mark, primary, Clarke, Matthew, primary, Crespo, Mateus, primary, Figueiredo, Ines, primary, Riisnaes, Ruth, primary, Sumanasuriya, Semini, primary, Rescigno, Pasquale, primary, Zafeiriou, Zafeiris, primary, Sharp, Adam, primary, Tunariu, Nina, primary, Bianchini, Diletta, primary, Gillman, Alexa, primary, Lord, Christopher J., primary, Hall, Emma, primary, Chinnaiyan, Arul M., primary, Carreira, Suzanne, primary, and de Bono, Johann S., primary

Published
2023
Full Text
View/download PDF

35. Supplementary Figure from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results

Author

Bundred, Nigel, primary, Porta, Nuria, primary, Brunt, Adrian Murray, primary, Cramer, Angela, primary, Hanby, Andrew, primary, Shaaban, Abeer M., primary, Rakha, Emad A., primary, Armstrong, Anne, primary, Cutress, Ramsey I., primary, Dodwell, David, primary, Emson, Marie A., primary, Evans, Abigail, primary, Hartup, Sue M., primary, Horgan, Kieran, primary, Miller, Sarah E., primary, McIntosh, Stuart A., primary, Morden, James P., primary, Naik, Jay, primary, Narayanan, Sankaran, primary, Ooi, Jane, primary, Skene, Anthony I., primary, Cameron, David A., primary, and Bliss, Judith M., primary

Published
2023
Full Text
View/download PDF

36. Tables from Characterizing CDK12-Mutated Prostate Cancers

Author

Rescigno, Pasquale, primary, Gurel, Bora, primary, Pereira, Rita, primary, Crespo, Mateus, primary, Rekowski, Jan, primary, Rediti, Mattia, primary, Barrero, Maialen, primary, Mateo, Joaquin, primary, Bianchini, Diletta, primary, Messina, Carlo, primary, Fenor de la Maza, Maria D., primary, Chandran, Khobe, primary, Carmichael, Juliet, primary, Guo, Christina, primary, Paschalis, Alec, primary, Sharp, Adam, primary, Seed, George, primary, Figueiredo, Ines, primary, Lambros, Maryou, primary, Miranda, Susana, primary, Ferreira, Ana, primary, Bertan, Claudia, primary, Riisnaes, Ruth, primary, Porta, Nuria, primary, Yuan, Wei, primary, Carreira, Suzanne, primary, and de Bono, Johann S., primary

Published
2023
Full Text
View/download PDF

37. Supplementary Data from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results

Author

Bundred, Nigel, primary, Porta, Nuria, primary, Brunt, Adrian Murray, primary, Cramer, Angela, primary, Hanby, Andrew, primary, Shaaban, Abeer M., primary, Rakha, Emad A., primary, Armstrong, Anne, primary, Cutress, Ramsey I., primary, Dodwell, David, primary, Emson, Marie A., primary, Evans, Abigail, primary, Hartup, Sue M., primary, Horgan, Kieran, primary, Miller, Sarah E., primary, McIntosh, Stuart A., primary, Morden, James P., primary, Naik, Jay, primary, Narayanan, Sankaran, primary, Ooi, Jane, primary, Skene, Anthony I., primary, Cameron, David A., primary, and Bliss, Judith M., primary

Published
2023
Full Text
View/download PDF

43. Abstract P2-13-08: Combined peri-operative lapatinib and trastuzumab in early HER2-positive breast cancer - Long term results of the randomized UK EPHOS-B trial

Author

Bundred, Nigel, primary, Porta, Nuria, additional, Brunt, Adrian Murray, additional, Cramer, Angela, additional, Hanby, Andrew, additional, Shaaban, Abeer, additional, Rakha, Emad, additional, Armstrong, Anne, additional, Cutress, Ramsey, additional, Dodwell, David, additional, Emson, Marie, additional, Evans, Abigail, additional, Hartup, Sue, additional, Horgan, Kieran, additional, McIntosh, Stuart, additional, Naik, Jay, additional, Narayanan, Samkaran, additional, Oii, Jane, additional, Skene, Anthony, additional, Cameron, David, additional, and Bliss, Judith, additional

Published
2022
Full Text
View/download PDF

44. Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results

Author

Bundred, Nigel, primary, Porta, Nuria, additional, Brunt, Adrian Murray, additional, Cramer, Angela, additional, Hanby, Andrew, additional, Shaaban, Abeer M., additional, Rakha, Emad A., additional, Armstrong, Anne, additional, Cutress, Ramsey I., additional, Dodwell, David, additional, Emson, Marie A., additional, Evans, Abigail, additional, Hartup, Sue M., additional, Horgan, Kieran, additional, Miller, Sarah E., additional, McIntosh, Stuart A., additional, Morden, James P., additional, Naik, Jay, additional, Narayanan, Sankaran, additional, Ooi, Jane, additional, Skene, Anthony I., additional, Cameron, David A., additional, and Bliss, Judith M., additional

Published
2022
Full Text
View/download PDF

46. OAB-060: Prospective comparison of contemporary whole body MRI and FDG PET/CT for disease detection and correlation with markers of disease burden in myeloma: results of the iTIMM trial

Author

Kaiser, Martin, primary, Porta, Nuria, additional, sharma, Bhupinder, additional, Levine, Daniel, additional, Koh, Dow-Mu, additional, Boyd, Kevin, additional, Pawlyn, Charlotte, additional, Ridell, Angela, additional, Downey, Katherine, additional, Croft, James, additional, Bonner, Alison, additional, Morgan, Veronica, additional, Stern, Simon, additional, Jones, Lydia, additional, Cheung, Betty, additional, Kyriakou, Charalampia, additional, Kaczmarek, Pawel, additional, Winfield, jessica, additional, Blackledge, Matthew, additional, Oyen, Wim, additional, and Messiou, Christina, additional

Published
2021
Full Text
View/download PDF

47. Prospective Evaluation of Whole-Body MRI versus FDG PET/CT for Lesion Detection in Participants with Myeloma

Author

Messiou, Christina, primary, Porta, Nuria, additional, Sharma, Bhupinder, additional, Levine, Daniel, additional, Koh, Dow-Mu, additional, Boyd, Kevin, additional, Pawlyn, Charlotte, additional, Riddell, Angela, additional, Downey, Katherine, additional, Croft, James, additional, Morgan, Veronica, additional, Stern, Simon, additional, Cheung, Betty, additional, Kyriakou, Charalampia, additional, Kaczmarek, Pawel, additional, Winfield, Jessica, additional, Blackledge, Matthew, additional, Oyen, Wim J. G., additional, and Kaiser, Martin F., additional

Published
2021
Full Text
View/download PDF

50. Hypofractionation: less is more?

Author

Mariam, Neethu Billy Graham, primary, Song, Yee Pei, additional, Joseph, Nuradh, additional, Hoskin, Peter, additional, Reeves, Kimberley, additional, Porta, Nuria, additional, James, Nicholas, additional, and Choudhury, Ananya, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results